Personalization of the choice of a therapeutic strategy for the treatment of type 2 diabetes mellitus: the focus on the original gliclazide MR (clinical cases)

• Inna V. Misnikova
• Yulia A. Kovaleva
• Svetlana Yu. Shokur

Abstract

There are a lot of drugs for the treatment of type 2 diabetes mellitus (T2DM), both new classes and long-used once. It makes necessary to know the action features of each drug in the class for optimal treatment, taking into account the emerging clinical problem. The article considers options for such a choice – a clinical case demonstrating the need for active antidiabetic therapy strategy with early onset of T2DM, as well as a clinical example that clearly demonstrates the possibility of effective administration of gliclazide MR without the risk of hypoglycemic conditions, which confirms the presence of intra-group differences in sulfonylureas in terms of the risk of hypoglycemia.

Keywords:gliclazide MR; low risks of hypoglycemia; early onset; personalized approach

References

1. Buse J.B., Wexler D.J., Tsapas A., et al. 2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2020; 63 (2): 221–8. DOI: https://doi.org/10.1007/s00125-019-05039-w; PMID: 31853556.

2. Dedov I.I., Shestakova M.V., Mayorov A. Yu., eds. Standards of specialized diabetes care. 10th edition. Sakharnyy diabet [Diabetes Mellitus]. 2021; 24 (1S): 1–148. DOI: https://doi.org/10.14341/DM12802 (in Russian)

3. Tomlinson B., Li Y.-H., Chan P. Evaluating gliclazide for the treatment of type 2 diabetes mellitus. Expert Opin Pharmacother. 2022; 23 (17): 1869–77. DOI: https://doi.org/10.1080/14656566.2022.2141108; PMID: 36300277.

4. Simpson S.H., Lee J., Choi S., et al. Mortality risk among sulfonylureas: a systematic review and network meta-analysis. Lancet Diabetes Endocrinol. 2015; 3 (1): 43–51. DOI: https://doi.org/10.1016/S-2213-8587(14)70213-X; PMID: 25466239.

5. Cordiner R.L.M., Mari A., Tura A., Pearson E.R. The impact of low-dose gliclazide on the incretin effect and indices of beta-cell function. J Clin Endocrinol Metab. 2021; 106 (7): 2036–46. DOI: https://doi.org/10.1210/clinem/dgab151; PMID: 33693776.

6. Laiteerapong N., Ham S.A., Gao Y., Moffet H.H., et al. The legacy effect in type 2 diabetes: impact of early glycemic control on future complications (The Diabetes & Aging Study). Diabetes Care. 2019; 42 (3): 416–26. DOI: https://doi.org/10.2337/dc17-1144; PMID: 30104301.

7. Morgunov L. Yu., Erina E.E. Glyclazide MR: obvious benefits. Endokrinologiya: novosti, mneniya, obuchenie [Endocrinology: News, Opinions, Training]. 2021; 10 (2): 74–81. DOI: https://doi.org/10.33029/2304-9529-2021-10-2-74-81 (in Russian)

8. Huo L., Magliano D.J., Rancière F., Harding J.L., et al. Impact of age at diagnosis and duration of type 2 diabetes on mortality in Australia 1997-2011. Diabetologia. 2018: 61 (5): 1055–63. DOI: https://doi.org/10.1007/s00125-018-4544-z; PMID: 29473119.

9. Misnikova I.V., Kovaleva Yu.A., Gubkina V.A. Early intensification of glucose-lowering therapy: VERIFY lessons and real clinical practice on the example of the Moscow region diabetes register data. Problemi Endocrinologii [Problems of Endocrinology]. 2020: 66 (5): 86–95. DOI: https://doi.org/10.14341/probl12696 (in Russian)

10. Peters S.A., Huxley R.R., Woodward M. Diabetes as a risk factor for stroke in women compared with men: a systematic review and meta-analysis of 64 cohorts, including 775,385 individuals and 12,539 strokes. Lancet. 2014: 383 (9933): 1973–80. DOI: https://doi.org/10.1016/S-0140-6736(14)60040-4; PMID: 24613026

11. Dreval’ A.V., Kovachev B.P., Misnikova I.V., Kovaleva Yu.A., et al. Study of new capacities in the evaluation of glycemic control in patients with type 2 diabetes. Problemi Endocrinologii [Problems of Endocrinology]. 2009: 55 (2): 35–40. DOI: https://doi.org/10.14341/probl200955235-40 (in Russian)

12. Kovatchev В.P., Cox D.J., Gonder-Frederick L., Clarke И.L. Methods for quantifying self-monitoring blood glucose profiles exemplified by an examination of blood glucose patterns in patients with type 1 and type 2 diabetes. Diabet Tech Ther. 2002: 4: 295–303. DOI: https://doi.org/10.1089/152091502760098438; PMID: 12165168.

13. Hassanein M., et al. A real-world study in patients with type 2 diabetes mellitus treated with gliclazide modified-release during fasting: DIA-RAMADAN. Diabetes Res Clin Pract. 2020: 163: 108154. DOI: https://doi.org/10.1016/j.diabres.2020.108154; PMID: 32330510.

14. Maloney A., Rosenstock J., Fonseca V. A model-based meta-analysis of 24 antihyperglycemic drugs for type 2 diabetes: Comparison of Treatment Effects at Therapeutic Doses. Clin Pharmacol Ther. 2019; 105 (5): 1213–23. DOI: https://doi.org/10.1016/j.diabres.2020.108154; PMID: 32330510.

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)